Your session is about to expire
← Back to Search
Lumify for Glaucoma Side Effects
Phase 4
Waitlist Available
Led By Ze Zhang, MD
Research Sponsored by Tulane University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Diagnosis of primary open angle glaucoma
Age > 18 years
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 60 minutes after application of eye drop
Awards & highlights
Study Summary
This trial will test whether Lumify can help reduce side effects for people with glaucoma who are already using another medication.
Who is the study for?
This trial is for adults over 18 with primary open-angle glaucoma who've been using Brimonidine eye drops (0.1%, 0.15%, or 0.2%) for more than six weeks and can consent to participate. It's not for pregnant individuals, prisoners, those with recent surgeries, lid surgery or botox history, allergies to brimonidine, or use of certain eye medications within the last week.Check my eligibility
What is being tested?
The study tests Lumify™ (Brimonidine Tartrate Ophthalmic Solution 0.025%) against a saline solution in glaucoma patients already on Brimonidine treatment. The focus is on its effects on ocular redness, intraocular pressure (IOP), and eyelid position.See study design
What are the potential side effects?
Lumify™ may cause minor eye irritation, dry mouth, drowsiness, or mild headaches as side effects based on previous knowledge about Brimonidine solutions used in similar concentrations.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I have been diagnosed with primary open angle glaucoma.
Select...
I am older than 18 years.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 60 minutes after application of eye drop
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~60 minutes after application of eye drop
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Intraocular pressure
Ocular redness
Secondary outcome measures
Eye discomfort
Palpebral fissure height
Trial Design
2Treatment groups
Experimental Treatment
Placebo Group
Group I: Lumify ArmExperimental Treatment1 Intervention
In each subject, each eye will be randomized to receive a single drop of either Lumify™ (brimonidine tartrate ophthalmic solution 0.025%) or a sterile balanced saline solution.
Group II: Control ArmPlacebo Group1 Intervention
In each subject, each eye will be randomized to receive a single drop of either Lumify™ (brimonidine tartrate ophthalmic solution 0.025%) or a sterile balanced saline solution.
Find a Location
Who is running the clinical trial?
Tulane UniversityLead Sponsor
117 Previous Clinical Trials
237,565 Total Patients Enrolled
Ze Zhang, MDPrincipal InvestigatorTulane University
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I cannot sit comfortably for 30 minutes.I haven't used eye whiteners or allergy drops in the last week.I have never had eyelid surgery or Botox injections.I have not had any surgery in the last 6 months.I have been diagnosed with primary open angle glaucoma.I don't have any major eye problems affecting redness, eye pressure, or eyelid position.You are allergic or sensitive to brimonidine.I am older than 18 years.I have been using brimonidine eye drops for more than 6 weeks.
Research Study Groups:
This trial has the following groups:- Group 1: Lumify Arm
- Group 2: Control Arm
Awards:
This trial has 2 awards, including:- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- Drug Has Already Been Approved - The FDA has already approved this drug, and is just seeking more data.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Share this study with friends
Copy Link
Messenger